quiflox
krka, d.d., novo mesto, slovēnija - marbofloxacin - tabletes - 20 mg - suņi
quiflox
krka, d.d., novo mesto, slovēnija - marbofloxacin - tabletes - 80 mg - suņi
cefaseptin
vetoquinol s.a., francija - cefaleksīns - tabletes - 75 mg - suņi
cefaseptin
vetoquinol s.a., francija - cefaleksīns - tabletes - 750 mg - suņi
anaprilīns 10 mg tabletes
olainfarm, as, latvia - propranolola hidrohlorīds - tablete - 10 mg
anaprilīns 40 mg tabletes
olainfarm, as, latvia - propranolola hidrohlorīds - tablete - 40 mg
sunitinib norameda 12,5 mg cietās kapsulas
norameda uab, lithuania - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib norameda 50 mg cietās kapsulas
norameda uab, lithuania - sunitinibs - kapsula, cietā - 50 mg
vidaza
bristol-myers squibb pharma eeig - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
xadago
zambon spa - safinamīdmetānsulfonāts - parkinsona slimība - anti-parkinsona zāles - xadago ir indicēts ārstēšana pieaugušiem pacientiem ar idiopātiska parkinsona slimība (pd) kā papildinājumu terapiju ar stabilu devu levodopa (l-dopa) atsevišķi vai kombinācijā ar citām pd zāles vidū-visaugstākās pakāpes svārstīgo pacientiem.